Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02670915 · ClinicalTrials.gov registry record · Phase 3
Efficacy and Safety of Faster-acting Insulin Aspart Compared to NovoRapid® Both in Combination With Insulin Degludec in Children and Adolescents With Type 1 Diabetes
A Phase 3 study, sponsored by Novo Nordisk A/S.
- Completed
- Registry status
- Phase 3
- Development phase
- 834
- Enrollment target
NCT02670915: Completed Phase 3 study, sponsored by Novo Nordisk A/S.
NCT02670915 is a Phase 3 study that has completed, run by Novo Nordisk A/S. The registered enrollment target is 834 participants, roughly in line with the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02670915, a Phase 3 study, has completed, sponsored by Novo Nordisk A/S.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 834 participants
- Enrollment target
Study Summary
This trial is conducted globally. The aim of the trial is to investigate efficacy and safety of faster-acting insulin aspart compared to NovoRapid® both in combination with insulin degludec in children and adolescents with type 1 diabetes.
Primary Outcome
Change from baseline (week 0) in glycosylated haemoglobin (HbA1c) was evaluated after 26 weeks of randomisation. The results are based on the last in-trial value, which included the last available measurement in the in-trial period. In-trial period: the observation period from date of randomisation until last trial-related participant-site contact and included data collected after a subject discontinued trial product.
Interventions
- DRUG insulin aspart
- DRUG Faster-acting insulin aspart
- DRUG insulin degludec
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 834 participants |
| Start Date | 2016-05-04 |
| Est. Completion | 2018-03-03 |
| Phase | Phase 3 |
What the finished NCT02670915 record still lists
NCT02670915 is an interventional study that assigns participants to a tested intervention. The registered 834 participants enrollment target is mid-sized for trials with a published cap, roughly in line with the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target.
The record links to 0 conditions, and to 3 interventions - of which insulin aspart is the first listed.
NCT02670915 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02670915 about?
NCT02670915 is a clinical study titled "Efficacy and Safety of Faster-acting Insulin Aspart Compared to NovoRapid® Both in Combination With Insulin Degludec in Children and Adolescents With Type 1 Diabetes". This trial is conducted globally. The aim of the trial is to investigate efficacy and safety of faster-acting insulin aspart compared to NovoRapid® both in combination with insulin degludec in children and adolescents with type 1 diabetes.
What is the current status of trial NCT02670915?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 834 participants. The study started on 2016-05-04. Estimated completion is 2018-03-03.
What interventions are being tested in trial NCT02670915?
The interventions under investigation include: insulin aspart (DRUG), Faster-acting insulin aspart (DRUG), insulin degludec (DRUG).
Who is sponsoring clinical trial NCT02670915?
This trial is sponsored by Novo Nordisk A/S, which has 431 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02670915's enrollment target sits among peer trials
834 397th of 2000 higher than 1,604 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03670524 · 835 participants · NA
Health, Environment and Action in Louisville (HEAL) Green Heart Louisville Project
- NCT02118467 · 836 participants · Phase 4
Vasoactive Drugs in Intensive Care Unit
- NCT06910553 · 832 participants
IBD Pregnancy Registry
- NCT07089706 · 832 participants · Phase 4
A Study to Evaluate the Immunogenicity and Safety of mRNA-1283 COVID-19 Variant-containing Formulations
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI